Meet Essilor® Stellest® lenses, the first and only FDA market authorized spectacle lens to slow myopia progression in children.*1
Click here to gain insights from EssilorLuxottica’s Monica Jong, BOptom, PhD, FAAO, FBCLA, Head of Medical Affairs, North America, about the introduction of Essilor® Stellest® lenses in the U.S., and how this innovation is poised to advance myopia management for children. Plus gain access to Essilor® Stellest® webinars tailored to optometrists, opticians and staff.
*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1Essilor International, data on file (2025).
